Download this White Paper to learn more.
Advances in cardiometabolic science are reshaping the treatment landscape for Type 1 diabetes (T1D), which is increasingly viewed as part of a broader cardiometabolic ecosystem.
As next-generation cell and gene therapies (CGTs) emerge, the field is shifting beyond lifelong insulin management toward biologic disease modification aimed at restoring endogenous insulin production and improving overall cardiometabolic health.
Realizing the full potential of these therapies requires more advanced, integrated biomarker strategies that enable precise patient identification and stratification, real-time immune and metabolic monitoring, more accurate risk assessment, and earlier detection of therapeutic response and safety signals.
This whitepaper explores the evolving intersection of T1D, cardiometabolism, and advanced therapeutics, including:
- The role of CGTs in redefining T1D treatment
- Emerging technologies designed to achieve durable metabolic control
- Why comprehensive biomarker strategies are foundational to advanced therapy success
- How to support disease characterization and monitoring, de-risk development, and guide decision-making across the cardiometabolic continuum
Offered Free by: Labcorp
See All Resources from: Labcorp
